Diplomat Pharmacy (NYSE:DPLO) Given Daily News Sentiment Score of 0.14

Press coverage about Diplomat Pharmacy (NYSE:DPLO) has trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.7678676175152 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Diplomat Pharmacy (NYSE DPLO) traded down $0.98 during midday trading on Friday, reaching $22.89. The company’s stock had a trading volume of 1,340,000 shares, compared to its average volume of 928,572. Diplomat Pharmacy has a 12 month low of $13.39 and a 12 month high of $27.78. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The stock has a market cap of $1,580.00, a P/E ratio of 190.75, a price-to-earnings-growth ratio of 3.46 and a beta of 1.05.

Several analysts have commented on the company. Deutsche Bank downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating and raised their target price for the company from $22.00 to $29.00 in a research report on Friday, February 2nd. Credit Suisse Group upgraded Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective on the stock in a research report on Thursday, January 25th. Mizuho set a $25.00 price objective on Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Lake Street Capital started coverage on Diplomat Pharmacy in a research report on Friday. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC raised their target price on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Diplomat Pharmacy currently has a consensus rating of “Buy” and a consensus target price of $23.95.

In other Diplomat Pharmacy news, Director Jeffrey G. Park bought 3,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were bought at an average price of $15.46 per share, for a total transaction of $46,380.00. Following the transaction, the director now owns 7,640 shares of the company’s stock, valued at approximately $118,114.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Joel Saban purchased 10,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average price of $15.24 per share, for a total transaction of $152,400.00. Following the acquisition, the president now owns 12,000 shares in the company, valued at $182,880. The disclosure for this purchase can be found here. Insiders have acquired a total of 15,000 shares of company stock worth $228,780 in the last quarter. 30.20% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Diplomat Pharmacy (NYSE:DPLO) Given Daily News Sentiment Score of 0.14” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/11/diplomat-pharmacy-dplo-receiving-somewhat-positive-media-coverage-report-finds.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Insider Buying and Selling by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply